Published in Clin Cancer Res on March 01, 2000
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer (2008) 1.13
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One (2013) 0.84
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemother Pharmacol (2008) 0.83
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study. Cancer (2009) 0.83
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets (2013) 0.81
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol (2014) 0.78
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer (2010) 0.77
Bartenders' respiratory health after establishment of smoke-free bars and taverns. JAMA (1998) 7.14
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
mTOR and cancer therapy. Oncogene (2006) 3.07
Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet (1993) 2.85
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
alpha-Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to Phyllanthus amarus. J Ethnopharmacol (2006) 2.38
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ (1990) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J Biol Chem (1999) 2.08
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry (1996) 1.92
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res (1999) 1.89
Alveolar soft part sarcoma in children and adolescents: clinical features and outcome of 11 patients. Med Pediatr Oncol (1996) 1.85
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
War Experiences with the Nonsuture Technic of Anastomosis in Primary Arterial Injuries. Ann Surg (1947) 1.84
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst (1998) 1.82
Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. J Clin Invest (1986) 1.77
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Hypercalcemia complicating childhood malignancies. Cancer (1993) 1.72
Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med (1988) 1.65
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J Clin Invest (1991) 1.63
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 1.60
Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry (1998) 1.59
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res (2001) 1.56
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55
Radiographic findings and Gs-alpha bioactivity studies and mutation screening in acrodysostosis indicate a different etiology from pseudohypoparathyroidism. Pediatr Radiol (2001) 1.54
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet (1993) 1.51
Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol (2000) 1.49
Veno-occlusive disease of the liver after chemotherapy for rhabdomyosarcoma: case report with a review of the literature. Med Pediatr Oncol (1995) 1.47
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res (1999) 1.47
Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood (1994) 1.45
Monoclonal antibodies to the myogenic regulatory protein MyoD1: epitope mapping and diagnostic utility. Cancer Res (1992) 1.43
Etoposide: an update. Clin Pharm (1989) 1.41
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol (1999) 1.41
Ratio of methotrexate to folate uptake by lymphoblasts in children with B-lineage acute lymphoblastic leukemia: a pilot study. J Pediatr Hematol Oncol (2000) 1.41
Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol (1998) 1.41
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2000) 1.41
A young woman with lymphoma and endocarditis. Lancet (1995) 1.38
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res (2000) 1.35
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol (1990) 1.34
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope (1998) 1.32
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Anti-inflammatory activities of the methanol extracts and an isolated furanoditerpene constituent of Sphenocentrum jollyanum Pierre (Menispermaceae). J Ethnopharmacol (2005) 1.29
Mechanisms of resistance to rapamycins. Drug Resist Updat (2001) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res (2000) 1.27
p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res (2001) 1.26
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1997) 1.25
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol (1992) 1.24
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol (2000) 1.22
Biological activities associated with the Facb fragment of rabbit IgG. Immunochemistry (1973) 1.21
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res (1979) 1.21
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest (1994) 1.19
Characterization of binding of simian rotavirus SA-11 to cultured epithelial cells. J Pediatr Gastroenterol Nutr (1988) 1.19
Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther (2012) 1.18
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol (1996) 1.18
Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer (2006) 1.17
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res (1987) 1.17
11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol (1994) 1.16
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res (2000) 1.16
Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine (2004) 1.15
An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther (2008) 1.15
An evaluation of the activity related to inflammation of four plants used in Thailand to treat arthritis. J Ethnopharmacol (2003) 1.14
Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. Cancer (2001) 1.14
Antibodies to distal carboxyl terminal epitopes in the v-fms-coded glycoprotein do not cross-react with the c-fms gene product. Virology (1986) 1.13
Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res (2000) 1.12
Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts. Br J Cancer (1977) 1.12
Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol (1994) 1.12
Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol (1994) 1.12
Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. stem bark, used in South Africa for skin lightening. J Ethnopharmacol (2008) 1.11
Dental abnormalities in children treated for acute lymphoblastic leukemia. Leukemia (1997) 1.10
Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol (1996) 1.10
Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet (1984) 1.10
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res (1981) 1.09
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol (1993) 1.08
The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin Oncol (1982) 1.07
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol (2001) 1.07
Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood (1994) 1.06
Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol (1999) 1.06
Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol (1990) 1.05
Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood. Bone Marrow Transplant (2000) 1.05
Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood (1992) 1.05
Antimicrobial and antiinflammatory activities of extracts and constituents of Oroxylum indicum (L.) Vent. Phytomedicine (1998) 1.05
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res (1997) 1.04